TipRanks
Advertisement
Advertisement
Mineralys Therapeutics Appoints New Chief Medical Officer
PremiumCompany AnnouncementsMineralys Therapeutics Appoints New Chief Medical Officer
1M ago
MLYS Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Premium
Pre-Earnings
MLYS Earnings Report this Week: Is It a Buy, Ahead of Earnings?
2M ago
Mineralys Therapeutics presents late-breaking data on lorundrostat
Premium
The Fly
Mineralys Therapeutics presents late-breaking data on lorundrostat
3M ago
Mineralys prices offering of 5.66M shares of common stock at $26.50
PremiumThe FlyMineralys prices offering of 5.66M shares of common stock at $26.50
4M ago
Mineralys Secures Lorundrostat Rights and Major Financing Facility
Premium
Company Announcements
Mineralys Secures Lorundrostat Rights and Major Financing Facility
4M ago
Mineralys to repurchase future royalty payments in Tanabe license agreement
Premium
The Fly
Mineralys to repurchase future royalty payments in Tanabe license agreement
4M ago
Jefferies says Baxfendy approval may be incrementally constructive for Mineralys
PremiumThe FlyJefferies says Baxfendy approval may be incrementally constructive for Mineralys
4M ago
Mineralys Therapeutics Maps Path After Lorundrostat NDA
Premium
Company Announcements
Mineralys Therapeutics Maps Path After Lorundrostat NDA
5M ago
Mineralys Therapeutics price target lowered to $42 from $49 at Goldman Sachs
Premium
The Fly
Mineralys Therapeutics price target lowered to $42 from $49 at Goldman Sachs
5M ago

Trending

Name
Price
Price Change
S&P 500
―
Dow Jones
―
Nasdaq 100
―